Additionally, the study demonstrated the metabolic consequences of hypophosphatemia in patients treated with iron carboxymaltose, which led to a decrease in 1,25-dihydroxy-vitamin D and an increase in parathyroid hormone and bone-specific alkaline phosphatase, along with a greater decrease in the anabolic bone marker P1NP [33]. This evidence concerns the gene PTH and hypophosphatemia.